The Effectiveness of Long-Term Continuation of Atezolizumab plus Bevacizumab in Patients Receiving Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Study
Liver function did not decrease even after long-term treatment with first-line Atez/Bev in patients who were able to progress to second-line therapy, indicating that long continuation of first-line Atez/Bev may be valuable for improving OS.
Authors
- Atsushi Ozasa
- Yoshihide Kimura (ORCID: https://orcid.org/0000-0003-4801-8384)
- Shunsuke Nojiri
- Kentaro Narita (ORCID: https://orcid.org/0000-0002-6504-9046)
- Katsumi Hayashi (ORCID: https://orcid.org/0000-0003-1092-2546)
- Kei Fujiwara (ORCID: https://orcid.org/0000-0003-4531-4444)
- Atsunori Kusakabe
- Hiromu Kondo (ORCID: https://orcid.org/0000-0002-1277-6821)
- Hiromi Kataoka (ORCID: https://orcid.org/0000-0001-9491-0723)
- Kohei Okayama
- Daisuke Kato (ORCID: https://orcid.org/0000-0003-1710-4319)
- Hayato Kawamura (ORCID: https://orcid.org/0000-0002-7679-4279)
- Tsutomu Mizoshita (ORCID: https://orcid.org/0000-0003-0460-5288)
- Kentaro Matsuura (ORCID: https://orcid.org/0009-0005-0163-3971)
- Takanori Suzuki (ORCID: https://orcid.org/0000-0002-8940-2393)
- Fumihiro Okumura
- Izumi Hasegawa
- Satoshi Sobue
Institutions
- Nagoya City University (JP)
- Gifu Prefectural Tajimi Hospital (JP)
- Toyokawa City Hospital (JP)
- Kasugai Municipal Hospital (JP)
- Nagasaki Rousai Hospital (JP)
- Chukyo Hospital (JP)
- Nagoya Medical Center (JP)
- Japanese Red Cross Nagoya Daini Hospital (JP)
Publication Details
- Journal
- Oncology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1159/000544051
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Ichihara International Scholarship Foundation
- Japan Society for the Promotion of Science